IL1B and gout: The NLRP3-IL-1β signaling pathway may play a role in the progression of gout combined with DED, and aberrant activation of NLRP3 inflammatory vesicles may be an initiator of gout and DED, and strategies that affect its activity or impede its activation could effectively inhibit the associated inflammatory response.